Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemokine receptor antagonist development.
Garin A, Johnson Z, Hermant A, Beltran F, Ratinaud Y, Michel A, Krohn S, Gaudet M, Carboni S, Ji H, Missotten M, Leger O, Power C, Proudfoot A. Garin A, et al. Among authors: gaudet m. Methods Mol Biol. 2013;1013:67-92. doi: 10.1007/978-1-62703-426-5_6. Methods Mol Biol. 2013. PMID: 23625494
Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
Crosignani S, Prêtre A, Jorand-Lebrun C, Fraboulet G, Seenisamy J, Augustine JK, Missotten M, Humbert Y, Cleva C, Abla N, Daff H, Schott O, Schneider M, Burgat-Charvillon F, Rivron D, Hamernig I, Arrighi JF, Gaudet M, Zimmerli SC, Juillard P, Johnson Z. Crosignani S, et al. Among authors: gaudet m. J Med Chem. 2011 Oct 27;54(20):7299-317. doi: 10.1021/jm200866y. Epub 2011 Oct 3. J Med Chem. 2011. PMID: 21916510
Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A. Crosignani S, et al. Among authors: gaudet m. J Med Chem. 2008 Apr 10;51(7):2227-43. doi: 10.1021/jm701383e. Epub 2008 Mar 5. J Med Chem. 2008. PMID: 18318469
Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.
Crosignani S, Jorand-Lebrun C, Campbell G, Prêtre A, Grippi-Vallotton T, Quattropani A, Bouscary-Desforges G, Bombrun A, Missotten M, Humbert Y, Frémaux C, Pâquet M, El Harkani K, Bradshaw CG, Cleva C, Abla N, Daff H, Schott O, Pittet PA, Arrighi JF, Gaudet M, Johnson Z. Crosignani S, et al. Among authors: gaudet m. ACS Med Chem Lett. 2011 Oct 10;2(12):938-42. doi: 10.1021/ml200223s. eCollection 2011 Dec 8. ACS Med Chem Lett. 2011. PMID: 24900284 Free PMC article.
Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.
Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H. Haselmayer P, et al. Among authors: gaudet m. Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. eCollection 2014. Front Immunol. 2014. PMID: 24904582 Free PMC article.
Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative.
Malik NH, Fu R, Hainc N, Noel CW, de Almeida JR, Hosni A, Huang SH, Yu E, Dzioba A, Leung A, Mangat A, MacNeil D, Nichols AC, Hiremath SB, Chakraborty S, Jooya A, Gaudet M, Johnson-Obaseki S, Whelan J, Forghani R, Hier MP, Morand G, Sultanem K, Dort J, Lysack J, Matthews W, Nakoneshny S, Gill G, Globerman A, Kerr P, Maralani P, Karam I, Eskander A. Malik NH, et al. Among authors: gaudet m. Head Neck. 2024 Mar;46(3):561-570. doi: 10.1002/hed.27608. Epub 2023 Dec 20. Head Neck. 2024. PMID: 38116716
334 results